Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

79 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL, Schaible TF, Van Deventer SJ. Rutgeerts P, et al. Among authors: van deventer sj, van hogezand ra. Gastroenterology. 1999 Oct;117(4):761-9. doi: 10.1016/s0016-5085(99)70332-x. Gastroenterology. 1999. PMID: 10500056 Clinical Trial.
Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project.
Cleynen I, González JR, Figueroa C, Franke A, McGovern D, Bortlík M, Crusius BJ, Vecchi M, Artieda M, Szczypiorska M, Bethge J, Arteta D, Ayala E, Danese S, van Hogezand RA, Panés J, Peña SA, Lukas M, Jewell DP, Schreiber S, Vermeire S, Sans M. Cleynen I, et al. Among authors: van hogezand ra. Gut. 2013 Nov;62(11):1556-65. doi: 10.1136/gutjnl-2011-300777. Epub 2012 Dec 21. Gut. 2013. PMID: 23263249
Is perianal Crohn's disease associated with intestinal fistulization?
Sachar DB, Bodian CA, Goldstein ES, Present DH, Bayless TM, Picco M, van Hogezand RA, Annese V, Schneider J, Korelitz BI, Cosnes J; Task Force on Clinical Phenotyping of the IOIBD. Sachar DB, et al. Among authors: van hogezand ra. Am J Gastroenterol. 2005 Jul;100(7):1547-9. doi: 10.1111/j.1572-0241.2005.40980.x. Am J Gastroenterol. 2005. PMID: 15984979
Effect of the anti-tumor necrosis factor-alpha antibody infliximab on the ex vivo mucosal matrix metalloproteinase-proteolytic phenotype in inflammatory bowel disease.
Meijer MJ, Mieremet-Ooms MA, van Duijn W, van der Zon AM, Hanemaaijer R, Verheijen JH, van Hogezand RA, Lamers CB, Verspaget HW. Meijer MJ, et al. Among authors: van der zon am, van hogezand ra, van duijn w. Inflamm Bowel Dis. 2007 Feb;13(2):200-10. doi: 10.1002/ibd.20051. Inflamm Bowel Dis. 2007. PMID: 17206679
Use of anti-tumour necrosis factor agents in inflammatory bowel disease. European guidelines for 2001-2003.
Schreiber S, Campieri M, Colombel JF, van Deventer SJ, Feagan B, Fedorak R, Forbes A, Gassull M, Gendre JP, van Hogezand RA, Lofberg R, Modigliani R, Pallone F, Petritsch W, Prantera C, Rampton D, Seibold F, Vatn M, Zeitz M, Rutgeerts P; BMBF Competence Network "Inflammatory Bowel disease". Schreiber S, et al. Among authors: van deventer sj, van hogezand ra. Int J Colorectal Dis. 2001 Feb;16(1):1-11; discussion 12-3. doi: 10.1007/s003840100285. Int J Colorectal Dis. 2001. PMID: 11317691
Effects of anti-tumour necrosis factor-alpha therapy on the quality of life in Crohn's disease.
van Balkom BP, Schoon EJ, Stockbrügger RW, Wolters FL, van Hogezand RA, van Deventer SJ, Oldenburg B, van Dullemen HM, Russel MG. van Balkom BP, et al. Among authors: van deventer sj, van hogezand ra, van dullemen hm. Aliment Pharmacol Ther. 2002 Jun;16(6):1101-7. doi: 10.1046/j.1365-2036.2002.01268.x. Aliment Pharmacol Ther. 2002. PMID: 12030951 Clinical Trial.
79 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page